The National Agency for Food and Drug Administration and Control has said it is set for Malaria Vaccine Clinical Trials all over Nigeria.
The Director General of NAFDAC, Prof. Mojisola Adeyeye, dropped the hint at the Pharmacovigilance Inspection interactive session with Pharma Stakeholders in Lagos, adding that the preparedness of the nation to begin Malaria Vaccine Clinical trial was in its resolve to exterminate the malaria scourge in Nigeria.
In a statement by NAFDAC, also mandated the pharmaceutical industry in Nigeria to establish Pharmacovigilance Surveillance Department as the Agency was set for full implementation of PV across the country.
Adeyeye explained that the pharmaceutical industry must put structures in place to ensure adequate monitoring of their products throughout the supply chain.
“The MAHs must as a matter of importance train and further engage all relevant stakeholders along their supply chain on the need for pharmacovigilance and use of relevant reporting platforms for reporting ADRs/AEFIs to the Agency.
“The sustained safety of medical products in Nigeria lies on a vast array of stakeholders and it has become imperative to continually improve on our pharmacovigilance processes for safety monitoring.
The National President of Community Pharmacists Association of Nigeria, Pharm. Wale Oladigbolu, commended NAFDAC for the initiative, stressing that “Although PV is not new, with this new approach we know that we will be dealing with the public in a very scientific manner to protect their health.’’
previous post
